Disclosing Agents as Photosensitizers in aPDT for Biofilm Control in Children
ConditionDental Plaque
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-7
SponsorUniversity of Nove de Julho
About this trial
This randomized controlled clinical trial aims to evaluate the effectiveness of plaque disclosing agents used as photosensitizers in antimicrobial photodynamic therapy (aPDT) for the control of dental biofilm in children aged 3 to 7 years. Participants will be allocated into groups to receive different treatment protocols, and biofilm levels will be assessed before and after the interventions. The primary outcome is the reduction of dental biofilm, aiming to determine whether disclosing agents can be an effective alternative photosensitizer in aPDT for pediatric patients.
Eligibility criteria
Qualifiers
Children aged 3 to 7 years
Both sexes
Good general health status
Classified as high caries risk according to the CAMBRA protocol (score ≥ +4 or presence of at least one disease indicator associated with two or more biological risk factors)
Disqualifiers
Presence of systemic diseases
Use of antibiotics within the last 30 days
Use of antimicrobial mouthwash within 48 hours prior to sample collection
Presence of structural dental alterations that may interfere with the standardization of the procedure
Trial design
Treatments tested in this trial
- Mechanical Prophylaxis
- aPDT with Erythrosine
- aPDT with GC TriPlaque ID Gel
Treatment groups
72 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov